Innovating for affordable healthcare

Shilpa Medicare Limited
Corporate & Admin Office:
"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India
Tel: +91-8532-238704, Fax: +91-8532-238876
Email: info@vbshilpa.com, Web: www.vbshilpa.com
CIN: L85110KA1987PLC008739

Date: 26 November 2026

To
Corporate relationship Department,
BSE Limited,
1st Floor, Rotunda Building
P.J Towers Dalal Street, Fort,
Mumbai 400001

National Stock Exchange of India, Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block, Bandra-Kurla Complex,
Bandra (E),
Mumbai 400051

Stock Code: BSE – 530549 / NSE – SHILPAMED

Dear Sir/Ma'am,

Sub: Receipt of Establishment Inspection Report (EIR) from USFDA for Unit VII of Shilpa Medicare Limited, Analytical Services Division, Hyderabad.

Ref: Regulation 30 of SEBI (LODR) Regulations, 2015

Further to our earlier intimation dated 18th September 2026, we wish to inform you that the Company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) with a **Voluntary Action Indicated (VAI) classification** for the Surveillance Inspection of Unit VII, Analytical Services Division and the inspection is now closed. The unit is at Plot No. 79, Road No. 15, Survey No. 125, IDA Mallapur, Nacharam, Uppal Mandal, Medchal-Malkajgiri Dist., Hyderabad, Telangana – 500076. The inspection was conducted from 16 September 2026 to 18 September 2026.

We are committed to upholding the highest standards of Quality and Compliance with continued focus on enhancement of our quality systems.

The above information is also available on the website of the Company www.vbshilpa.com

For SHILPA MEDICARE LIMITED

RITU TIWARY Digitally signed by RITU TIWARY Date: 2026.11.26 11:44:00 +05'30'

Ritu Tiwary
Company Secretary & Compliance Officer